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Exposure to environmental mutagens is an important cause of human cancer, and measures to reduce mutagenic
and carcinogenic exposures have been highly successful at controlling cancer. Until recently, it has been possible to
connect the chemical characteristics of mutagens to actual mutations observed in human tumors only indirectly.
Now, next-generation sequencing technology enables us to observe in detail the DNA-sequence-level effects of
well-known mutagens, such as ultraviolet radiation and tobacco smoke, as well as endogenous mutagenic
processes, such as those involving activated DNA cytidine deaminases (APOBECs). We can also observe the effects
of less well-known but potent mutagens, including those recently found to be present in some herbal remedies.
Crucially, we can now tease apart the superimposed effects of several mutational exposures and processes and
determine which ones occurred during the development of individual tumors. Here, we review advances in
detecting these mutation signatures and discuss the implications for surveillance and prevention of cancer. The
number of sequenced tumors from diverse cancer types and multiple geographic regions is growing explosively, and
the genomes of these tumors will bear the signatures of even more diverse mutagenic exposures. Thus, we envision
development of wide-ranging compendia of mutation signatures from tumors and a concerted effort to experimentally
elucidate the signatures of a large number of mutagens. This information will be used to link signatures observed in
tumors to the exposures responsible for them, which will offer unprecedented opportunities for prevention.New opportunities for detecting mutagen
exposures in human tumors
Mutagenic environmental exposures are important causes
of human cancer. This was first understood from Percival
Pott's 18th century epidemiological observation of scrotal
cancer in chimney sweeps [1]. Causality was eventually
confirmed experimentally by using coal tar to induce can-
cer in rabbits [2]. Soon thereafter, polycyclic aromatic hy-
drocarbons were identified as carcinogens in coal tar [3].
Much later, once the role of DNA as an information mol-
ecule was understood, the biochemical mechanisms for
polycyclic aromatic hydrocarbon mutagenesis were eluci-
dated [4]. This led to a broader appreciation of the roles of
DNA damaging agents in mutagenesis and to extensive
study of numerous other mutagens [5,6]. Subsequently,* Correspondence: steve.rozen@duke-nus.edu.sg
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reproduction in any medium, provided the orassays for mutagenicity became proxies for tests of carcino-
genicity, with the Ames test, performed in a bacterial system,
as a well-known example [7]. However, tests of mutagenicity
in artificial systems do not fully connect mutagenic expo-
sures to the patterns of mutation observed in cancers.
More recently, it has become clear that specific mutagens
produce characteristic patterns of somatic mutations in the
DNA of malignant cells. We describe these patterns, called
'mutation signatures', in detail below. Briefly, mutation
signatures usually include the relative frequencies of the
various nucleotide mutations (such as A >C, A >G, A >T,
C >A) plus, ideally, their trinucleotide contexts, that is, the
identities of the bases on both sides of the mutated nucleo-
tides. Previously, our knowledge of these signatures was
based on short lengths (such as a few kilobases) of DNA
sequence. With the advent of next-generation sequencing,
it is now possible to infer these signatures from the se-
quences of all the exons in the genome ('whole exome') or
from the sequence of the entire genome ('whole genome').td. The licensee has exclusive rights to distribute this article, in any medium, for
time, the article is available under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mutations across whole exomes or genomes offers several
advantages over previous approaches, including that many
more mutations can be detected, which provides far greater
statistical power and allows the parsing of the superimposed
mutation signatures stemming from several exposures. Ac-
tual mutation signatures are the end result of a series of bio-
chemical and biological processes, including the metabolism
of pro-mutagens to active forms, biochemical damage to





















Figure 1 Linking mutation signatures to exposures or endogenous m
mutagen at a time or (b) study mixtures of signatures. One can study sign
(d) via observation of mutation signatures in the exome or genome seque
tumor exomes harbor only a handful of somatic point mutations, and pres
many cancers, typical numbers of somatic point mutations in exomes are 6
mutations per exome [13]. Typical numbers for genomes of cancers such a
mutated genomes harbor >400,000 somatic point mutations [16]. Among e
observe mutations in short sequences. This allows inference of relatively sim
nucleotide mutations. (f) By sequencing the exome, or, ideally, the genom
informative, extended signature, for example one that includes the trinucle
extended signatures by sequencing the exomes or genomes of tumors wit
from mixtures of signatures (b) requires somatic mutation catalogs from th
studies have looked at thousands of catalogs. (i) Procedures based on NMF
a set of extended mutation signatures and the contributions of each inferred
from mixtures of signatures (j) can be matched to extended signatures that w
exposures (h), thereby providing information on (l) exposures that contribute
extended signatures extracted from mixtures can be correlated with informat
allowing inference of the causes of mutation signatures (l). (n) The causes ofselection for or against the resulting mutations. Thus, while
not obviating the need for mechanistic studies of the bio-
chemical mechanisms of mutagenicity, cataloging mutations
by next-generation sequencing provides information about a
critical endpoint: the actual mutations that occur in cell lines
or in human cancers in response to mutagenic exposures.
The long-term promise is that the epidemiological connec-
tion of specific mutagens to signatures actually observed in
tumors will indicate which mutagenic exposures are true sub-
stantial contributors to the burden of human cancer (Figure 1).(b) 
(i) 
Mixtures of mutation signatures
Somatic mutation catalogs
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atures of single mutagens either (c) via experimental approaches, or
nce of tumors with a known predominant mutational exposure. Some
umably these tumors arise from causes other than mutagenesis. For
0 to 300 [9-12]. Highly mutated cancers sometimes have >3,500
s those of the lung or stomach are >15,000 [14,15], and a few highly
xperimental approaches, one can use (e) reporter constructs and
ple signatures, for example (g) signatures involving only single
e of a mutagen-exposed, clonal cell line, one can (h) infer a more
otide contexts of single-nucleotide mutations. One can also infer
h known, predominant exposures (d). Extraction of mutation signatures
e exomes or genomes of large numbers of tumors. The most recent
(non-negative matrix factorization) allow (j) simultaneous inference of
signature to each tumor's mutations. (k) Extended signatures derived
ere experimentally determined or inferred from known predominant
d to tumors with mixtures of mutation signatures. (m) Alternatively,
ion on mutagenic exposures or on endogenous mutagenic factors,
some signatures will remain unknown and require further research.
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also implicate previously unsuspected exposures in par-
ticular cancers. This information on causal exposures
then could provide foci for prevention efforts. Neverthe-
less, despite the low cost and ubiquity of next-generation
sequencing, detailed mutation signatures of only a few
known carcinogens have been elucidated experimentally
so far. Indeed, in a recent groundbreaking survey of mu-
tation signatures across many types of human cancers,
most mutation signatures are ascribed to particular expo-
sures by statistical association rather than recapitulation
of the signatures in experimental systems [8].
We describe below the state of the art for determining
mutation signatures by next-generation sequencing, the
implications of this approach for detecting the carcino-
genic impacts of mutagenic exposures, and its promise
for prevention. We start by describing signatures of sin-











A > T (C|T)AG > (C|T)TG [16-19]
UV radiation C > T;strand
bias; CC > TT
TC > TT (C|T)C > (C|T)T [6,8,9,21-23]
Tobacco
smoke
Primarily C > A,
some C > G
and C > T
CG > AGCG > TG;CG > GG [8,14,24-26]
Aflatoxin B1 Primary G > T;
some G > A
NA [29-34]
Temozolomide C > T CC > TC; CT > TT [8,36,37]





















C > T CG > TG [8]
*The ' > ' symbol indicates a change from one nucleotide to another; a vertical lineapart superimposed signatures from multiple mutagenic
processes, and conclude with a vision of how this could
improve prevention.
Signatures of single mutagens
To date, the signatures of carcinogenic mutagens have
been established either in vitro or in human cancers that
are primarily caused by one exposure (Table 1). We
elaborate first on the mutation signature of aristolochic
acid (AA), which has been established both in vitro and
in human cancers [16-19]. AA is a powerful mutagen
that is found in some herbal remedies and that causes
upper urinary-tract urothelial cancer (UTUC) [16-19]. It
also probably contributes to liver cancer (hepatocellular
carcinoma, HCC) [16]. Thus, in addition to providing an
example of the signature of a single mutagen, AA also il-
lustrates the use of signatures to detect likely carcino-
genic exposures that were previously unsuspected.utagenic processes
Prevalence Challenges
Widely used in traditional
medicines [20]; exposure to AA is
widespread in Taiwan [17]
No unusual challenges




evidence of the role of tobacco




[29,35] Signature in extended context
not known
Present in 10% of glioblastomas;
9% of melanoma [8]
No unusual challenges
Exposure associated with risk of
leukemia [39,40]
Several mutagenic metabolites
and signature in extended
context not known
Present in 16 tumor types [8] Signatures 2 and 13 are similar
[8], except 2 has C > T and 13
has higher C > G
Present in 13.7% of uterus cancer
and 36.7% of colorectal cancer [8]
No unusual challenges
Present in 9 tumor types [8] No unusual challenges
A majority of tumors of most
types have this signature [8]
Interpretation of two similar
signatures in [8] not clear
indicates alternative nucleotides. NA, not applicable.
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AA is a natural compound found in plants in the genus
Aristolochia (Figure 2a). These plants are used in trad-
itional herbal remedies for weight loss and a plethora
of health problems, including menstrual symptoms,
snakebites, rheumatism, arthritis, and gout [43,44].
Although challenging to document, the use of these
plants probably remains widespread [20,45]. Indeed, 99N 
+ 











Figure 2 Mechanisms of mutagenesis of aristolochic acid and UV ligh
aristolochic acid. Aristolochic acid I is shown; in aristolochic acid II, OCH3 is
aristolactam nitrenium ions by one or more of several enzymes, including N
P450, family 1, subfamily A, polypeptide 2), and NADPH-hemoprotein reduc
with adenosine bases, and (f) these adducts lead to A > T mutations. (g) Py
pyrimidine dimers (CPD). (i) Either the cytosine (C) (left) or the CC dipyrimi
denotes pyrimidine. (j) Error-free trans-lesion DNA synthesis (TLS) induces C
DNA replication of the U-containing DNA strand (k). Photograph of Aristolo
from [14], with permission from Oxford University Press.species in the genus are known to be used medicinally,
and although the AA content of most species is unknown,
23 of the medicinally used species contain AA [46]. AA is
metabolized to aristolactam nitrenium ions, which form
covalent adducts with adenosines in DNA (Figure 2b-e)
[45,47]. These adducts then lead to A > T mutations
(mutations from adenine to thymine; Figure 2f ). These
were initially observed as somatic mutations in theUltraviolet light 
(h) Cyclobutane pyrimidine dimers 
(i) Deamination 
3′Py C 
(j) Error free TLS 
3′Py U 
3′Py U 
5′ 3′C C 
5′ 3′U U 
5′ 3′U U 





3′ 5′T T 
C>T mutation CC>TT mutation
(g) Pyrimidine
t. Preparations of (a) plants from the genus Aristolochia contain (b)
replaced by H. Aristolochic acid is (c) metabolically activated to (d)
QO1 (NAD(P)H dehydrogenase, quinone 1), CYP1A2 (cytochrome
tase [45]. (e) The aristolactam nitrenium ions form covalent adducts
rimidines exposed to ultraviolet (UV) radiation form (h) cyclobutane
dines in CPD (right) undergo deamination, resulting in uracil (U). Py
> T and CC > TT mutations at the sites of U-containing CPDs through
chia plant (a) by ST Pang. Molecule schematics in (b-e) reproduced
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Taiwan, and the Balkans [17,47]. This was highly unusual,
as A > T mutations are rare in other types of human
cancer, including UTUCs unrelated to AA exposure [18].
Furthermore, the AA-associated mutations in TP53
tended to occur in the context of CAG >CTG (C followed
by the mutated A followed by G, in 5' to 3' order) [19].
However, analysis of approximately 1 kb of sequence
in a single gene (TP53) [19] offers limited statistical
power to determine the sequence contexts in which the
A > T mutations occur. In addition, the approach of
assessing physical mutation signatures in TP53, a key
tumor suppressor gene, runs the risk of bias caused by
conflation of physical mutation signatures with the ef-
fects of intense selection during tumor evolution.
Recently, high-throughput next-generation sequencing
has provided the means to catalog and analyze somatic
mutations far more completely, whether by whole-
exome or whole-genome sequencing. Recent work has
shown a remarkable preponderance of A > T mutations
in AA-associated UTUCs from Taiwan (Figure 3a)
[16-19]. For comparison, in gastric cancer or other non-
AA-associated cancers, A > T somatic mutations are rare
(Figure 3b) [8,14,24].
By way of technical explanation, if we consider a single
DNA strand as a point of reference, there are 12 possible
single-nucleotide mutations: four nucleotides times three
possible mutations for each nucleotide. In some parts of
the genome, it makes sense to use a particular strand as
the reference sequence. In particular, in regions of the
genome that are transcribed, we can use the transcribed
strand, that is, the strand that serves as a template for
the RNA polymerase, as the point of reference. However,
in the non-transcribed regions, neither strand in particu-
lar is the obvious choice for the reference sequence.
Therefore, the usual practice in the study of mutation
signatures has been to not distinguish complementary
mutations, but rather to group them together. For ex-
ample, A > C mutations are grouped with the comple-
mentary T > G mutations, A > G mutations are grouped
with T > C mutations, and so on.
With the availability of catalogs of somatic mutations
from sequencing data, it has become possible to investigate
the nucleotides that neighbor AA-induced A >T mutations.
The trinucleotide sequence contexts of AA-associated mu-
tations show a dramatic overrepresentation of cytosines
and thymines immediately 5′ of mutated adenines (that is,
[C|T]A; mutated adenine in bold) and overrepresentation
of guanines 3′ of mutated adenines (that is, AG)
(Figure 3c) [16-19]. This preference of A > T mutations
for the (C|T)AG context has not been observed in non-
AA-associated cancers (such as gastric cancer; Figure 3d),
suggesting that this sequence context is a particular
characteristic of AA mutagenesis.In addition, the A > T mutations in AA-associated
UTUCs are less common on the transcribed strands of
genes than on the non-transcribed strands (Figure 3e).
This strand bias suggests that AA adducts occurring on
the transcribed strand were often corrected by
transcription-coupled nucleotide excision repair. Similar
strand bias is not seen for the relatively infrequent A > T
mutations seen in other cancers, such as gastric cancer
(Figure 3f ).
An AA-like signature in liver cancer
Unexpectedly, recent examination of mutation signa-
tures in hepatitis B virus-exposed human HCCs revealed
some with obvious AA-like signatures (Figure 3g,h) [16],
although this cancer type apparently was not previously
linked to AA exposure [48]. The signature shows a large
proportion of A > T somatic mutations with strand bias
(as seen in AA-exposed UTUCs; Figure 3e,g) and a tri-
nucleotide context that strongly resembles that in AA-
associated UTUC (compare Figure 3c and Figure 3h). It
is possible that exposure to AA in conjunction with
hepatitis B virus infection may contribute synergistically
to HCC formation, much as hepatitis and aflatoxin do
(see below). As AA had not been previously implicated
as a risk factor for HCC, this finding may represent a
new paradigm, in which environmental exposures contrib-
uting to specific cancers are deduced from observations of
mutation signatures. It is likely that Aristolochia-containing
herbal remedies are the source of AA exposure in these
cancers. If so, appropriate measures to minimize exposure
should be taken - for example, through education and
more aggressive enforcement of bans on Aristolochia-
containing remedies.
Ultraviolet radiation
Ultraviolet (UV) radiation induces several kinds of muta-
tions, primarily C > T (Figure 2g-k, Table 1) [6,9]. It also
induces double mutations CC > TT, in which adjacent
cytosines mutate to thymines as a result of cytosine di-
mers generated by UV light. Earlier studies indicated
that UV-induced C > T mutations often occur after a
pyrimidine (C or T) [9,21,22]. Analysis of mutation cata-
logs from melanomas indicates that the trinucleotide
context is often TCC [8]. As with AA-induced A > T
mutations, there is strand bias: UV-induced mutations
are less likely to occur on the transcribed strand [8].
Tobacco smoke
Tobacco smoking causes the vast majority of lung can-
cers and contributes strongly to many other cancers, in-
cluding liver, colorectal, breast, prostate, and bladder
cancers [49]. Tobacco smoke contains many mutagenic
carcinogens, including polycyclic aromatic hydrocarbons
and N-nitrosamines [25,50,51]. The mutation signature
(c) 
(d) 
(e) (f) (g) 
(h) 
AA-UTUC exomes
Gastric cancer exomes 
Exomes from probable AA-exposed HCC tumors
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Figure 3 (See legend on next page.)
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Figure 3 Aristolochic acid signatures in upper urinary-tract urothelial cancer and hepatocellular carcinoma. (a,b) Mean counts of each of
six different somatic single-nucleotide mutations in exome data from (a) AA-associated UTUCs (AA-UTUC, n = 9) and (b) gastric cancers (n = 15).
(c,d) Trinucleotide contexts for somatic mutations in (c) AA-UTUCs (n = 9) and (d) gastric cancers (n = 15). The height of each bar (the y axis)
represents the proportion of all observed mutations that fall into a particular trinucleotide mutational class, for example CAG > CTG and TAG >
CTG (indicated). Along the x axis the mutations are organized first by the nucleotide mutation itself: C > T (blue bars), C > G (black bars), C > A
(red bars), A > T (gray bars), A > G (green bars), A > C (pink bars). For each single-nucleotide mutation (such as A > T) there are 16 possible trinucle-
otide contexts (AAA > ATA, AAC > ATC, and so on) The heights of the bars indicate the observed proportions of mutations aggregated over all
exomes studied. (e,f) Mean counts of somatic single-nucleotide mutations in (e) AA-associated UTUCs (n = 9) and (f) gastric cancer (n = 15),
shown separately for non-transcribed (N) and transcribed (T) strands. The lower mutation counts on the transcribed strand suggest transcription-
coupled repair (see main text). (f) Analogous data for gastric cancer do not show strand bias (n = 15). (g) Probable AA-exposed HCCs show a
preponderance of A > T mutations with strand bias similar to that observed in AA-associated UTUCs (n = 11). (h) Trinucleotide context for
mutations in probable AA-exposed HCC is highly similar to that for AA-associated UTUCs (c). Plotted using data from [16].
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of the TP53 gene, in which exposure to tobacco-smoke
mutagens often results in G > T mutations [25]. Only a
few studies extended the mutation signature to a trinu-
cleotide context, and the preference for particular nucle-
otides 5' or 3' of the mutated nucleotides is weak
(Table 1) [8,24], possibly reflecting the complex mix of
mutagens present in tobacco smoke. There are chal-
lenges in dissecting the tobacco-smoke mutation signa-
ture, because the signatures from different constituent
mutagens are likely to differ, and their effects on differ-
ent organs and tissues are also likely to differ [51]. Thus,
it would be highly informative to examine experimen-
tally the signatures of individual mutagenic components
of tobacco smoke in the genomes of exposed cell lines
from different tissues (Figure 1f ).
Aflatoxin B1
Aflatoxins are byproducts of mold growing on food [52],
and among the aflatoxins, aflatoxin B1 (AFB1) is thought
to be the most carcinogenic and is the most studied
[53]. The International Agency for Research on Cancer
(IARC) classifies AFB1 as a Group I carcinogen (an
agent that is definitely carcinogenic to humans) [54].
AFB1 is metabolized to an epoxide compound that can
form a covalent bond with the N7 atom of guanine,
thereby leading to G > T mutations (Table 1) [35]. In
addition, AFB1 can induce 8-hydroxy-2'-deoxyguanosine,
which also produces predominantly G > T mutations in
in vitro experimental models [52]. The mutation signature
of AFB1 has been primarily studied in the TP53 gene, and
indeed particular somatic mutations in TP53 are used as
biomarkers for aflatoxin exposure in tumors [55,56]. How-
ever, the extended mutation signature of AFB1 has not
been studied (Table 1). Exposure to AFB1 is through food,
but unfortunately, its contamination in food is difficult to
detect. Consequently, convincing evidence that AFB1 is
carcinogenic relied on studies showing that people with
AFB1-derived adducts were more likely to develop cancer
[29,35]. The predominant cancer associated with AFB1 is
HCC, and the risk associated with combined AFB1exposure and hepatitis infection is far greater than each
individual risk [29,35].
Temozolomide
Temozolomide is an alkylating agent commonly used
for chemotherapeutic treatment of melanoma and cen-
tral nervous system tumors [57,58]. Temozolomide is
quickly absorbed and undergoes spontaneous break-
down to form an active compound (methyltriazen-1-yl
imidazole-4-carboxamide), which forms several DNA
adducts: N7-methylguanine (70%), N3-methyladenine
(9%), and O6-methylguanine (5%) [59]. Both the N7-
methylguanine and N3-methyladenine lesions are
rapidly repaired by base excision repair [60]. However, the
O6-methylguanine adducts sometimes are not repaired,
leading to point mutations [61,62]. Although the mecha-
nisms of temozolomide genotoxicity have been intensively
studied in a therapeutic context, to our knowledge, the
mutation signature of temozolomide has not been studied
in experimental systems. However, Alexandrov et al. [8]
detected a clear association between a CC > TC signature
and temozolomide treatment in glioblastoma and mela-
noma patients (Table 1).
Benzene
Occupational exposure to benzene is of particular con-
cern, as it is widely used in a variety of industries, in-
cluding manufacture of petrochemicals and other
chemicals, as well as in manufacture of shoes, lubricants,
dyes, detergents, drugs, and pesticides [63]. Non-
occupational exposures occur from automobile exhaust
and gasoline fumes, industrial emissions, and especially
cigarette smoking and second hand smoke [63]. Benzene
is classified as a Group 1 carcinogen by IARC [64]. It is
benzene's metabolites, such as phenol, hydroquinone,
and related hydroxyl metabolites, that have been linked
to leukemia in experimental models in vitro and in vivo
[65,66]. Benzene metabolites can exert their genotoxic
effect through the formation of DNA adducts, oxidative
stress, damage to the mitotic apparatus, and inhibition
of topoisomerase II function [65]. Although the
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mutation signature is poorly understood. Thus far, re-
search using a reporter gene has found a preponderance
of C > T and C > A mutations [38] (Table 1). However,
there has been no genome-wide analysis of benzene's
mutation signature in cell line models or in benzene-
associated leukemias.
Endogenous mutagenic processes
There are also endogenous mutagenic processes, which
are sometimes unleashed during cancer development.
For example, the APOBEC genes encode DNA cytidine








































































Figure 4 Mutation signatures in lung adenocarcinoma. (a-d) Four sign
organized as in Figure 3c. However, unlike in Figure 3c, the y axes in these
observed signatures. (a) Signature of APOBEC-induced mutagenesis. (b) 'Ag
smoke. (d) 'Signature 5' from [8], due to an unknown exposure or mutation
are overlays of several of the signatures above. Signature R2 is an additiona
adapted from [8] with permission from Macmillan Publishers Ltd.C > T mutations especially in the TC(A|T) context
(mutated base in bold; Figure 4a, Table 1) [41,42,67].
Endogenous mutagenic processes arising in cancer devel-
opment can also consist of inactivation of DNA repair
or proofreading mechanisms. A well-known example is
microsatellite instability, caused by defects in the DNA
mismatch repair mechanism [68]. As another example,
it was recently shown that, in some cancers, inactivation
of the proofreading domain of DNA polymerase delta 1
or epsilon (POLD1 or POLE) leads to very high mutation
rates [13]. POLE mutations were associated with very





h somatic mutations per Mb < 15 and > 7.5
T>A T>C T>G
atures that are prominent in lung adenocarcinoma [8]. The x axes are
plots represent proportions of mutations in inferred rather than
e 1B', one of two signatures that correlated with age. (c) Tobacco
al process. (e) Almost all lung adenocarcinomas have mutations that
l signature that may partly represent sequencing errors [8]. All panels
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opment, and the majority of tumors are diagnosed in
older patients [69-71]. DNA damage and mutations ac-
cumulate with age [72]. Interestingly, there are different
age-related mutation patterns in different tissues due to
differences in functional characteristics such as mitotic
rate, transcriptional activity, metabolism, and specific
DNA repair mechanisms [73]. Two distinct yet similar
age-related mutation signatures have been detected in
cancers (Table 1), and at least one of the two is present
in the overwhelming majority of tumors [8].
Mixtures of signatures
In most tumors, somatic mutation catalogs comprise the
superimposed results of several mutational exposures and
processes. For example, lung adenocarcinomas usually
show the signature of tobacco smoke [8,14,24] (Figure 4c).
In addition, these tumors often simultaneously show mu-
tation signatures due to exposure to endogenous activated
DNA cytidine deaminases (APOBECs; Figure 4a), signa-
tures of mutations that accumulate with age (Figure 4b),
and other signatures of unknown origin [8] (Figure 4d).
Given that the catalog of somatic mutations in a
tumor often represents an overlay of several mutational
processes, a key challenge is to dissect out and assess
the contribution of each process. Building on initial
work [74], recent strides have been made in computa-
tional techniques for meeting this challenge. Specifically,
it is now possible to simultaneously discover the existence
of multiple signatures and assess the relative contribution
of each signature to each tumor's catalog of somatic mu-
tations [8,75,76]. Figure 5 explains the process of com-
bining three mutation signatures to reconstruct a close
approximation to the observed somatic mutation cata-
log of a tumor.
Discovering the signatures relies on a computational
analysis called non-negative matrix factorization (NMF).
The input to NMF consists of the observed catalogs of
somatic mutations from tens [75] to several thousands
[8] of tumors. For each of the observed catalogs (one for
each tumor), NMF sets up an equation such as the one
shown in Figure 5. Then, for a pre-specified number, N,
of undefined component signatures, NMF finds the N
specific signatures and the contributions of each specific
signature (the 'pie chart' circle, Figure 5b) that, for all
the tumors simultaneously, provide the closest recon-
structions of the observed catalogs. In its mathematical
formulation, the collection of mutation catalogs (Figure 5d)
is the approximate product of the matrix representing the
mutation signatures (Figure 5a) and the matrix represent-
ing the contributions of each signature to each tumor
(Figure 5b). In other words, Figure 5a and Figure 5b are
factors that, when multiplied, yield an approximation of
Figure 5d. These factors are constrained to be non-negative, because one cannot have a negative contribution
of a mutation signature to a tumor, and because a muta-
tion signature cannot have a negative proportion of muta-
tions of a given class; this is the origin of the term
non-negative matrix factorization. We emphasize that
NMF simultaneously detects the signatures present in the
somatic mutation catalogs of multiple tumors and deter-
mines the contribution of each signature to the somatic
mutations in each tumor.
There are, of course, numerous fine points, salient
among which is the question of how to find the right
number, N, of signatures. This depends on the num-
ber of mutation catalogs (and the number of muta-
tions) available for analysis, as well as on the actual
diversity of mutational processes represented in the
sampled tumors. A large international effort recently
generated somatic mutation catalogs from 7,042 tu-
mors encompassing 30 cancer types, and these cata-
logs allowed discernment of 21 mutation signatures
[8]. Across all the tumors analyzed, every cancer type
had at least two mutation signatures; the cancers with
the most signatures were those of the liver (seven sig-
natures) and stomach and uterus (six signatures
each). Figure 4e shows the example of lung adenocar-
cinomas, which usually show mixtures of several mu-
tational processes.
Based on association with clinically documented expo-
sures or correspondence to previously known mutational
profiles, the origins of 11 of the 21 signatures in [8] were
identifiable. Three signatures were attributed to exogen-
ous exposures: tobacco smoke, UV radiation, and temozo-
lomide. Other signatures were attributed to endogenous
processes, including activation of APOBEC genes, mis-
match repair deficiency, mutations in the POLE gene, and
mutations in the BRCA1 or BRCA2 breast cancer genes.
Finally, there were two signatures for which the level of
the contribution to mutations in tumors was strongly
correlated with the patient's age.
Despite the power conferred by analysis of mutation
signatures across the 7,042 tumors, the environmental
or biological factors underlying 10 of the 21 signatures
could not be identified, and indeed only three signatures
were linked to exogenous exposures [8]. Furthermore,
over two-thirds of the cancer types studied harbored sig-
natures of unknown source. Thus, there is a large gap in
our understanding of the environmental exposures and
mutational processes that contribute to common human
cancers. Conversely, there are mutagens with well-
studied biochemistry - for example, aflatoxins [30], ben-
zene [66], and AA - that were not detected in these
tumors. Possibly none or few of the 7,042 tumors ana-
lyzed had been exposed to these mutagens. Indeed, it
seems likely that none were exposed to AA, which has a
very distinctive signature that would have been detected
(a) Mutation signatures 
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Figure 5 Reconstructing the catalog of somatic mutations in a
cancer genome as superimposed mutation signatures at
varying levels of exposure. (a) Each signature is represented by
one of the bar charts, and consists of the relative proportions of
different types of mutations in that signature. For example, in
Signature 1, C > T mutations make up almost half of the total
number of mutations, whereas T > A mutations constitute only
about 10% of the total. (b) Each of the three signatures contributes
a different number of mutations to the actual catalog, represented
in the 'pie chart'. In this example, Signature 1 contributes 1,000
mutations, Signature 2 contributes 1,500, and Signature 3
contributes 750. The 1,000 mutations from Signature 1 are allocated
according to the bar chart that represents the proportions of
different types of mutations in this signature. In this case, Signature
1 would contribute approximately 50% × 1,000 = 500C > T mutations.
Signature 2 would contribute approximately 9% × 1,500 = 135C > T
mutations. Signature 3 would contribute approximately 10% × 750 =
75C > T mutations. The total number of C > T mutations in the
reconstructed catalog would be 500 + 135 + 75 = 710. The
reconstruction of the (d) actual catalog is approximate, and in this
example, the reconstruction does not account for 65 mutations,
approximately 2% of the total in the actual mutation catalog - the
gray noisy line in (c). This figure is a simplification; in fact, in
references [8,75,76], signatures are composed of nucleotide
mutations in their trinucleotide contexts, as shown in Figures 3c,d,h
and 4a-d. The mathematical procedures for approximating observed
catalogs from mixtures of trinucleotide signatures are the same, but
the trinucleotide context provides far more useful information: for
example, the spikes in AA-exposed UTUCs show that the AA-
induced A > T mutations tend to occur in a (C|T)AG trinucleotide
context. Reproduced from [76] with permission from Elsevier.
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important environmental exposures were not repre-
sented among the 7,042 tumors. Because environmental
exposures vary widely by geography, it will be important
to determine somatic mutation catalogs from a diversity
of geographic regions. For example, we previously
showed that different genes are mutated in cholangiocar-
cinomas from different geographical regions and with
different etiologies [10,11]. In addition, it is crucially im-
portant to have detailed clinical information associated
with somatic mutation catalogs. It is possible that the
mutagenic exposures responsible for some signatures in
previous studies [8] could not be identified because the
relevant clinical information was not available. For ex-
ample, exposures to compounds such as aflatoxins
would probably not be captured in clinical records. It is
also possible that the mutation signatures of some expo-
sures were not detected because the trinucleotide con-
text and other characteristics of the mutations have not
been determined from biochemical studies.
The examples of signatures described above focus on
single-nucleotide mutations within trinucleotide con-
texts as the main distinguishing features of signatures.
However, other characteristics of mutation catalogs can
also be included as features of mutation signatures and
analyzed by NMF [8,76]. For example, strand bias could
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for each class of mutation in transcribed regions; in this
case one would consider C > T on the transcribed strand
to be distinct from G > A (the complementary mutation).
Other types of mutations, including small insertions and
deletions and dinucleotide mutations such as those that
occur as a result of UV exposure (CC > TT mutations),
can also be included as features of mutation signatures.
The framework can also be expanded to consider more
bases adjacent to the mutated nucleotide - for example,
a pentanucleotide rather than a trinucleotide context.
The framework can also be applied to specific regions of
the genome. For example, the APOBEC signature (Fig-
ure 4a) shows strand bias in exons, but not in introns
[76]. Given that both exons and introns are transcribed,
the exonic strand bias does not seem to be the result of
transcription-coupled repair, and the underlying mech-
anism remains unknown. However, by distinguishing
mutations according to whether they occur in exons or
introns, this information could be used to generate a
more informative mutation signature. The utility of
these possible extensions remains untested, but is likely
to increase as additional tumor genomes, which capture
about 50 times more mutation information than exomes,
are sequenced.
Mutation signatures for surveillance and
prevention
Much of cancer is associated with exogenous exposures,
and therefore in principle amenable to control by avoid-
ance of those exposures. Examples include tobacco
smoke, UV light, and many infectious exposures, such as
hepatitis B and C, human papilloma virus, and Helicobacter
pylori [77-79]. IARC lists 422 known or likely exogenous
carcinogens [80]. Indeed, prevention by avoidance of ex-
ogenous carcinogenic exposures has been an effective long-
term strategy for the control of cancer, with tobacco smok-
ing as the most salient example [49,81]. However, evidence
from recent work [8] indicates that many exogenous expo-
sures remain unidentified. Notably, as described earlier, of
the 21 mutation signatures identified in [8], 10 lacked any
known underlying mutational process or exposure, and
over two-thirds of cancer types were affected by signatures
due to unknown causes. Furthermore, only three exogen-
ous mutagens were identified: tobacco smoking (12% of all
tumors), UV light (5% of all tumors), and temozolomide
(0.5% of all tumors), and the cause of Signature 5 (found in
14% of all tumors) is unknown. Some cancers were dispro-
portionately affected by signatures with unknown causes.
For example, 89% of HCCs showed Signature 12, and 90%
showed Signature 16, both with unknown causes. Con-
versely, the signatures of some well-known mutagens were
not detected (Table 1), suggesting that cancers due to these
mutagens were rare or non-existent among the 7,042tumors studied. This implies that the signatures of many
exposures have yet to be captured in sequenced tumor
exomes or genomes. Thus, the analysis of mutation signa-
tures in catalogs of somatic mutations from tumors is
promising but in its infancy. To realize this promise, we
must extend our knowledge in two aspects.
The first is to expand the diversities of tumor types and
of their geographical origins. There is already rapid growth
in the number of sequenced cancer genomes and their cat-
alogs of somatic mutations. An important advantage of
next-generation sequencing in this endeavor is that it is
based on an inexpensive, commodity technology, the price
of which will continue to drop. In addition, next-generation
sequencing provides direct readouts of the mutations that
actually occur in tumors. In this context, we note that using
whole-exome or whole-genome sequencing to detect muta-
tions (rather than sequencing targeted, cancer-related
genes) ensures that most mutations detected are selectively
inconsequential passengers. Even though a few somatic
mutations in whole-exome or whole-genome sequence are
drivers, they are so few that they have negligible influence
on the signature. Finally, the large amount of data gener-
ated by whole-exome and especially whole-genome sequen-
cing provides optimal statistical power to tease apart the
signatures of different mutational processes or exposures.
The second aspect in which we must extend our
knowledge consists of establishing connections between
specific mutagens and their mutation signatures. This is
likely to require experimental exposure of cells or ani-
mals to mutagens or their biochemically active metabo-
lites, followed by next-generation sequencing of either
clonal populations of exposed cells or of tumors that de-
velop in exposed animals. Sequencing of the exposed ge-
nomes will connect specific mutagens to their mutation
signatures in far more detail than is currently available.
When mutation signatures cannot be found among the
signatures of known mutagens, this would suggest the
effects of an unknown exposure or mutational process,
and point to the need for further epidemiological, toxi-
cological, or biological research.
To our knowledge, there has been little work toward
this goal, and our work on the mutation signature of AA
and its application to detect AA exposure in HCC is an
example [16].
Conclusions and future directions
We envision that the groundbreaking technical advances
for detection of signatures in genome- and exome-wide
catalogs of somatic mutations from thousands of tumors
will enable the assembly of a wide-ranging compendium
of mutation signatures from diverse cancer types and
multiple geographical regions. This compendium would
contain many more whole-genome catalogs of somatic
mutations (as opposed to exome catalogs) than are
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many more geographical regions, thus capturing a much
wider range of mutagenic exposures. This compendium
could be combined with experimental determination of
the extended signatures of known and suspected muta-
gens, including, when necessary, their signatures in dif-
ferent tissues or cell types. Signatures with known
causes would represent future opportunities for preven-
tion. Signatures with unknown causes would point to
the need for further investigation of exogenous muta-
gens or endogenous mutation processes.
The first part of this vision, the assembly of a com-
pendium of mutation signatures from ever more cancer
genomes, seems certain to happen because of the plum-
meting cost of sequencing and the many ongoing ef-
forts to sequence tumor genomes. Nevertheless, there
are many open questions on how best to deploy NMF
or NMF-related procedures to assemble this compendium.
For example, what factors determine the power of these
procedures to distinguish similar mutation signatures? As
the number of genome-wide somatic mutation catalogs
increases, will it become worthwhile to include additional
information, such as strand bias or pentanucleotide
context, in mutation signatures? Fortunately, NMF-
related procedures are an active area of machine learning
research. For example, enhanced NMF procedures that
prefer sparser solutions - solutions in which the mutation
catalog of a given tumor is modeled as the mixture of a
relatively small number of signatures - have been recently
proposed [82-85]. Other proposed enhanced NMF proce-
dures could favor solutions with fewer mutation signatures
contributing to each tumor, leading to more interpretable
results [85-87].
The second part of the vision, the experimental elu-
cidation of signatures and the investigation of possible
causes of signatures with unknown causes, will re-
quire concerted effort. There will surely be challenges
in understanding the signatures of complex mutagens
such as tobacco smoke, and challenges in understand-
ing the differences in the mutagens' metabolisms and
mutagenic activity across different tissues and cell
types. Nevertheless, in the near term it will be pos-
sible to dissect and refine the worldwide repertoire of
signatures and to assign some of these signatures to
known causes as experimental studies advance. Of course,
not all cancer is due to mutagenic exposures, but linking
somatic mutation catalogs generated by next-generation
sequencing to specific exposures via the mutation signa-
tures of these exposures could substantially reduce the
burden of avoidable cancer.
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